Combination of Empagliflozin and Metformin Therapy: A Consideration of its Place in Type 2 Diabetes Therapy

Clinical Medicine Insights. Endocrinology and Diabetes
Jennifer D Goldman

Abstract

Type 2 diabetes mellitus (T2DM) is characterized by multiple metabolic abnormalities and current approaches to treatment involve a stepwise approach, frequently involving the use of combination therapy. The addition of the sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, to metformin therapy has been shown to be effective and well tolerated in patients with T2DM and is 1 of the several recommended treatment options. The publication of the EMPA-REG OUTCOME study, which showed that empagliflozin is associated with cardiovascular (CV) and renal benefits, has resulted in changes in treatment guidelines for T2DM. Because many patients with T2DM will require treatment with more than 1 glucose-lowering agent, consideration of the role of empagliflozin in combination therapy is relevant. The clinical data reviewed show that the combination of empagliflozin/metformin offers the potential to improve glycemic control in T2DM and reduces body weight and blood pressure, vs each agent individually, with a manageable risk profile. This combination could be suitable for patients with T2DM who are inadequately controlled by metformin, in particular, for patients who would benefit from modest reductions in blood pressure and body...Continue Reading

References

Oct 29, 2008·Archives of Internal Medicine·Elizabeth SelvinFrederick L Brancati
Jan 22, 2010·The Cochrane Database of Systematic Reviews·Shelley R SalpeterEdwin E Salpeter Posthumous
Feb 5, 2011·Postgraduate Medicine·Serge Jabbour, Barry Ziring
Jul 26, 2011·Primary Care Diabetes·Hamida KhanTahseen A Chowdhury
Oct 1, 2011·Diabetes, Obesity & Metabolism·R A DeFronzoS Del Prato
Dec 21, 2012·International Journal of Clinical Pharmacology and Therapeutics·Sreeraj MachaHans J Woerle
Feb 19, 2013·Diabetes Care·Sarah Stark CasagrandeCatherine C Cowie
Feb 21, 2013·Current Atherosclerosis Reports·Saloua El MessaoudiNiels P Riksen
Aug 2, 2013·Diabetes Care·Ralph A DeFronzoMuhammad Abdul-Ghani
Jan 28, 2014·The Journal of Clinical Investigation·Ele FerranniniHans-Juergen Woerle
Apr 12, 2014·Diabetes Care·Hans-Ulrich HäringUNKNOWN EMPA-REG MET Trial Investigators
Jun 21, 2014·The Lancet. Diabetes & Endocrinology·Martin RidderstråleUNKNOWN EMPA-REG H2H-SU trial investigators
Jun 3, 2015·Diabetic Medicine : a Journal of the British Diabetic Association·L MerkerUNKNOWN EMPA-REG EXTEND MET investigators
Jul 4, 2015·Clinical Therapeutics·Christopher S KovacsUNKNOWN EMPA-REG EXTEND™ PIO investigators
Sep 2, 2015·Diabetes Research and Clinical Practice·Hans-Ulrich HaeringUNKNOWN EMPA-REG EXTEND™ METSU investigators
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Jan 9, 2016·The Journal of Endocrinology·Hongying An, Ling He
Mar 5, 2016·International Journal of Clinical Pharmacology and Therapeutics·Christina RojasSreeraj Macha
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jul 22, 2016·Diabetes Care·Avivit Cahn, William T Cefalu
Jan 18, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Feb 6, 2017·Drugs·Cristina BianchiStefano Del Prato
May 19, 2017·Diabetes, Obesity & Metabolism·Benedetta Maria BonoraGian Paolo Fadini
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Jul 31, 2019·Phytotherapy Research : PTR·Reyhaneh Moradi-MarjanehAmirhossein Sahebkar

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01131676
NCT01719003
NCT01649297
NCT00749190
NCT00789035
NCT00881530
NCT01159600
NCT01289990
NCT01167881
NCT01422876

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.